EPO Enlarged Board of Appeal issues G 2/21 decision

Board provides guidance on evidence submitted after patent filing date | Eagerly awaited decision confirms what’s needed to prove a certain effect.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

Compugen’s anti-PVRIG patent upheld by the EPO

18 July 2023 Opposition Division ruling supports the use of immunotherapy patent | Highlights the significance of plausibility in patent evaluation following G 2/21.

Europe

Pharma patent filings rise at EPO amid pandemic

5 April 2022 Patent applications in Europe reached record levels during 2021 amid the COVID-19 pandemic, according to a new report by the European Patent Office.

Biotechnology

EPO’s new examination guidelines: what you need to know

6 April 2021 The updated rules included important changes involving amino or nucleic acid sequences and antibodies, as Clare Roskell and Samantha Moodie of Mathys & Squire explain.

More on this story

Biotechnology

Compugen’s anti-PVRIG patent upheld by the EPO

18 July 2023 Opposition Division ruling supports the use of immunotherapy patent | Highlights the significance of plausibility in patent evaluation following G 2/21.

Europe

Pharma patent filings rise at EPO amid pandemic

5 April 2022 Patent applications in Europe reached record levels during 2021 amid the COVID-19 pandemic, according to a new report by the European Patent Office.

Biotechnology

EPO’s new examination guidelines: what you need to know

6 April 2021 The updated rules included important changes involving amino or nucleic acid sequences and antibodies, as Clare Roskell and Samantha Moodie of Mathys & Squire explain.

More on this story

Biotechnology

Compugen’s anti-PVRIG patent upheld by the EPO

18 July 2023 Opposition Division ruling supports the use of immunotherapy patent | Highlights the significance of plausibility in patent evaluation following G 2/21.

Europe

Pharma patent filings rise at EPO amid pandemic

5 April 2022 Patent applications in Europe reached record levels during 2021 amid the COVID-19 pandemic, according to a new report by the European Patent Office.

Biotechnology

EPO’s new examination guidelines: what you need to know

6 April 2021 The updated rules included important changes involving amino or nucleic acid sequences and antibodies, as Clare Roskell and Samantha Moodie of Mathys & Squire explain.

More features

Life sciences leaders recognised at LSPN Awards USA 2025

UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body

LSPN: Counsel grapple with AI’s impact on training and critical thinking

'Nothing can stand in the way of our work': Ukraine resumes IP system

LSPN: Trump's policy storm causing chaos and confusion

Taylor Wessing expands in Europe with Paris team

LSPN: Using ‘the patentee’s friend’ in Section 112 claims

ResMed voids sleep apnoea tech patent at PTAB

EPO Enlarged Board of Appeal issues G 2/21 decision

More on this story

Editor's picks

Editor's picks

More on this story

More on this story

More features